Beam Therapeutics Inc. — Q2 2023 Form 10-Q Summary
Business context and reporting period
Beam is an early-stage biotechnology company developing precision genetic medicines based on base-editing and delivery technologies. The company has no product sales and relies primarily on license and collaboration revenue, equity offerings, and strategic collaborations. This Form 10-Q covers the quarter and six months ended June 30, 2023; it was filed August 8, 2023.
Key financial metrics
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| License and collaboration revenue | $20.1 million, up from $16.7 million | $44.3 million, up from $25.1 million |
| Research and development expense | $97.6 million, up from $74.6 million | $197.3 million, up from $140.0 million |
| General and administrative expense | $24.7 million, up from $24.1 million | $48.1 million, up from $43.3 million |
| Loss from operations | $102.1 million | $201.1 million |
| Net loss | $82.8 million, or $1.08 per share | $179.2 million, or $2.41 per share |
| Net loss in comparable 2022 period | $72.0 million, or $1.02 per share | $141.2 million, or $2.03 per share |
| Cash flow from operating activities | Not separately presented in the filing summary | $(194.5) million |
Calculated loss margins were approximately 508% at the operating level and 412% at the net level for the quarter, reflecting that reported revenue consists primarily of collaboration accounting rather than product sales. For the six months, the corresponding margins were approximately 454% and 404%.
At June 30, 2023, Beam had $225.5 million of cash and cash equivalents, $847.5 million of marketable securities, and $15.4 million of restricted cash. Cash, cash equivalents, and marketable securities totaled approximately $1.1 billion. Total liabilities were $542.2 million, including $1.8 million of equipment financing liabilities, $175.3 million of lease liabilities, and $295.3 million of deferred revenue. The company reported no conventional material borrowings beyond equipment financing; lease obligations remain significant.
Material changes versus the prior comparable period
- Quarterly revenue increased 20.8%, while six-month revenue increased 76.7%, primarily from Pfizer, Apellis, and Orbital collaboration arrangements.
- Quarterly research and development expense increased $23.1 million, and six-month expense increased $57.3 million, driven by clinical work for BEAM-101 and BEAM-201, IND-enabling work for BEAM-301 and BEAM-302, manufacturing operations, LNP development, employee growth, and facility costs.
- Six-month operating cash flow shifted from $166.2 million provided in 2022 to $194.5 million used in 2023. The 2022 inflow was unusually aided by collection of the $300.0 million Pfizer upfront payment.
- Financing activities provided $206.0 million in the first six months of 2023, including $201.6 million from equity offerings. The company sold 5.8 million shares under its ATM program during the first half of 2023 and had sold 9.7 million additional shares for aggregate gross proceeds of $528.2 million as of June 30, 2023.
- Shares outstanding increased to 77.95 million at June 30, 2023 from 71.28 million at December 31, 2022, indicating meaningful equity dilution.
- Stock-based compensation increased to $50.2 million for the first six months from $39.6 million in the prior-year period.
Guidance, outlook, commentary, and risks
- Management expects continued operating losses and negative operating cash flow for the foreseeable future and states that June 30, 2023 cash, cash equivalents, and marketable securities should fund operations and capital expenditures for at least 12 months from issuance of the financial statements.
- Management expects to require additional capital and may use equity or debt financings, collaborations, strategic alliances, and licensing arrangements. No committed external source of capital is identified.
- Beam expects to continue enrolling patients in the BEAM-101 BEACON trial, with a target of 45 treated patients, and plans to report data from multiple patients in 2024.
- The first BEAM-201 patient was expected to be dosed in the third quarter of 2023. The planned Phase 1 portion includes up to 48 patients, followed by an approximately 48-patient Phase 2 portion.
- The company plans to submit a regulatory application for BEAM-302 in the first quarter of 2024 and for BEAM-301 in the first half of 2024.
- Beam’s 100,000-square-foot North Carolina manufacturing facility became operational in the first quarter of 2023, with cGMP operations expected to begin in late 2023. Execution, qualification, and operating costs remain important uncertainties.
- A research institution alleges breach of confidentiality, trade-secret misappropriation, unfair practices, and unjust enrichment involving technology related to, among other programs, BEAM-102 and BEAM-302. Beam accrued $3.4 million based on an unsuccessful settlement proposal; the filing states that the ultimate outcome could materially differ and that no complaint had been filed as of June 30, 2023.
- Key risks include clinical-trial enrollment and treatment delays, uncertain regulatory outcomes, third-party intellectual-property claims, dependence on contract manufacturers and suppliers, availability of non-human primates for preclinical work, manufacturing execution, equity dilution, and the need for additional financing.
Most important facts for investors to verify
- Progress, safety, enrollment, and 2024 data timing for the BEAM-101 and BEAM-201 clinical programs.
- Whether BEAM-302 and BEAM-301 regulatory submissions occur on the stated timelines.
- Actual cash burn, remaining ATM capacity, additional equity issuance, and the duration of the stated cash runway.
- Qualification and initiation of cGMP operations at the North Carolina facility and the related capital and operating costs.
- Resolution and potential financial impact of the research institution dispute.
- Material intellectual-property developments, including third-party patent challenges and licensing requirements.
- Future collaboration revenue, deferred-revenue recognition, partner opt-in decisions, milestones, royalties, and the risk that revenue will not recur at current levels.